Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia

Sang Kyun Sohn, Suk Joong Oh, Byung Soo Kim, Hun Mo Ryoo, Joo Seop Chung, Young Don Joo, Soo Mee Bang, Chul Won Jung, Dong Hwan Kim, Sung Soo Yoon, Ho In Kim, Hong Ghi Lee, Jong Ho Won, Yoo Hong Min, June Won Cheong, Joon Seong Park, Ki Seong Eom, Myung Soo Hyun, Min Kyoung Kim, Hawk KimMoo Rim Park, Jinny Park, Chul Soo Kim, Hyeoung Joon Kim, Yeo Kyeoung Kim, Eun Kyung Park, Dae Young Zang, Deog Yeon Jo, Joon Ho Moon, Seon Yang Park

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or molecular responses, we measured trough IM levels in patients with chronic myeloid leukemia, chronic phase (CML-CP), at 6 months of treatment with a standard dose of IM. Eighty-seven newly diagnosed patients with CML-CP were prospectively enrolled. Seventy-eight patients (89.7%) showed an optimal response (complete or partial cytogenetic response) at 6 months. Trough IM levels were 1378 ± 725 ng/mL. When categorized into two groups, there was a statistically significant difference in numbers of patients with optimal and suboptimal responses at 6 months (group with <1000: 80.6% vs. 19.4%; ≥1000: 94.6% vs. 5.4%; p = 0.032), and in numbers of patients with early major molecular response (early-MMR) and without MMR at 6 months (group with <1000: 3.2% vs. 96.8%; ≥1000: 21.4% vs. 78.6%; p = 0.047). In conclusion, the incidence of optimal cytogenetic response or early-MMR in patients with CML-CP treated with IM for 6 months was significantly higher in those with a trough level of ≥1000 compared with those with a level of <1000. Dose escalation of IM can be one option in patients with CML showing suboptimal response or resistance to the standard dose of IM, especially with low trough plasma IM levels (<1000 ng/mL).

Original languageEnglish
Pages (from-to)1024-1029
Number of pages6
JournalLeukemia and Lymphoma
Volume52
Issue number6
DOIs
Publication statusPublished - 2011 Jun 1

    Fingerprint

Keywords

  • Chronic myeloid leukemia
  • cytogenetic response
  • imatinib
  • molecular response
  • trough blood level

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Sohn, S. K., Oh, S. J., Kim, B. S., Ryoo, H. M., Chung, J. S., Joo, Y. D., Bang, S. M., Jung, C. W., Kim, D. H., Yoon, S. S., Kim, H. I., Lee, H. G., Won, J. H., Min, Y. H., Cheong, J. W., Park, J. S., Eom, K. S., Hyun, M. S., Kim, M. K., ... Park, S. Y. (2011). Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leukemia and Lymphoma, 52(6), 1024-1029. https://doi.org/10.3109/10428194.2011.563885